Bio­Th­eryX col­lects $92M in Se­ries E round; WuXi Bi­o­log­ics ups its stake in an emerg­ing ADC play­er

Bio­Th­eryX is con­tin­u­ing to rake in in­vestor cap­i­tal, net­ting a fresh $92 mil­lion Se­ries E round on Thurs­day.

The San Diego-based com­pa­ny not­ed it will fund at least two spe­cif­ic pro­grams in its an­nounce­ment: BTX-A51 and BTX-1188. The for­mer, Bio­Th­eryX’s lead can­di­date, is a mul­ti-ki­nase in­hibitor look­ing at p53 pro­tein mod­u­la­tion in acute myeloid leukemia, myelodys­plas­tic syn­drome and sol­id tu­mors. BTX-A51 is cur­rent­ly in a Phase I tri­al for r/r AML.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.